AN2 Therapeutics Q3 EPS $(0.65) Beats $(0.70) Estimate
Portfolio Pulse from Benzinga Newsdesk
AN2 Therapeutics (NASDAQ:ANTX) reported Q3 losses of $(0.65) per share, beating the analyst consensus estimate of $(0.70) by 7.14%. However, this represents a 10.17% increase in losses compared to the same period last year.
November 09, 2023 | 10:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AN2 Therapeutics reported better than expected Q3 losses, but the losses increased compared to last year.
While AN2 Therapeutics beat the consensus estimate, the increase in losses compared to the same period last year could potentially offset any positive sentiment. The impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100